Compare IONQ & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONQ | ILMN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 20.5B |
| IPO Year | N/A | 2000 |
| Metric | IONQ | ILMN |
|---|---|---|
| Price | $38.28 | $135.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 17 |
| Target Price | $73.75 | ★ $125.71 |
| AVG Volume (30 Days) | ★ 20.5M | 2.1M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.46 |
| Revenue | $79,836,000.00 | ★ $4,288,000,000.00 |
| Revenue This Year | $153.55 | N/A |
| Revenue Next Year | $81.42 | $2.79 |
| P/E Ratio | ★ N/A | $31.64 |
| Revenue Growth | ★ 113.07 | N/A |
| 52 Week Low | $17.88 | $68.70 |
| 52 Week High | $84.64 | $155.53 |
| Indicator | IONQ | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 40.68 |
| Support Level | $42.84 | $147.57 |
| Resistance Level | $46.90 | $153.48 |
| Average True Range (ATR) | 4.07 | 5.52 |
| MACD | -1.12 | -1.90 |
| Stochastic Oscillator | 7.44 | 3.90 |
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.